Last reviewed · How we verify
Oral Sorafenib
Sorafenib is a multi-kinase inhibitor that blocks RAF, VEGFR, and PDGFR signaling to inhibit tumor cell proliferation and angiogenesis.
Sorafenib is a multi-kinase inhibitor that blocks RAF, VEGFR, and PDGFR signaling to inhibit tumor cell proliferation and angiogenesis. Used for Hepatocellular carcinoma, Renal cell carcinoma, Differentiated thyroid cancer.
At a glance
| Generic name | Oral Sorafenib |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | Multi-kinase inhibitor |
| Target | RAF, VEGFR-2, VEGFR-3, PDGFR-β |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Sorafenib inhibits multiple serine/threonine and receptor tyrosine kinases, including RAF kinase (involved in the MAPK pathway), VEGFR-2 and VEGFR-3 (which promote tumor angiogenesis), and PDGFR-β (which supports tumor vasculature). By blocking these pathways, sorafenib reduces both direct tumor cell growth and the formation of new blood vessels that tumors depend on for survival.
Approved indications
- Hepatocellular carcinoma
- Renal cell carcinoma
- Differentiated thyroid cancer
Common side effects
- Hand-foot skin reaction
- Diarrhea
- Fatigue
- Hypertension
- Rash
- Nausea
- Alopecia
Key clinical trials
- Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma (PHASE1)
- MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib (PHASE3)
- Phase 2 Study of WGI-0301 for Advanced HCC (PHASE2)
- Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients (PHASE1, PHASE2)
- PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy (PHASE2)
- Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab (PHASE2)
- CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC
- FLT3-ITD Targeted Therapy in Fit AML Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Sorafenib CI brief — competitive landscape report
- Oral Sorafenib updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI